Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
panobinostat + docetaxel + prednisone
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Panobinostat + docetaxel + prednisone is an experimental combination therapy evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). **Panobinostat** is a pan-histone deacetylase (HDAC) inhibitor that induces cell cycle arrest and apoptosis by modulating gene expression. **Docetaxel** is a taxane-class cytotoxic chemotherapeutic that inhibits microtubule depolymerization, causing cell-cycle arrest at the G2/M phase. **Prednisone** is a synthetic glucocorticoid used for its anti-inflammatory and immunosuppressive properties, and also commonly paired with docetaxel in mCRPC to reduce some side effects and possibly enhance efficacy. This combination was tested in phase I trials to determine safety and early indications of activity in castration-resistant prostate cancer, showing some preliminary evidence of PSA reduction and feasibility for further study[1][3][6].
- Brand names
- Farydak (for panobinostat)
02
Targets
TUBB (Tubulin (alpha and beta subunits))GR (Glucocorticoid receptor)HDAC (HDAC family)
Beyond the preview
Go deeper on panobinostat + docetaxel + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on panobinostat + docetaxel + prednisone.